1. Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
    Daniela Gentile et al, 2020, Medical Oncology CrossRef
  2. LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat
    Jitka Široká et al, 2018, Journal of Chromatography B CrossRef
  3. Development of potential inhibitors of cell division protein kinase 2 by ligand based drug design
    Vildan Enisoğlu Atalay et al, 2021, Main Group Chemistry CrossRef
  4. Therapeutic advances in anaplastic thyroid cancer: a current perspective
    Shikha Saini et al, 2018, Molecular Cancer CrossRef
  5. Effects of nutraceuticals on anaplastic thyroid cancer cells
    Lorenzo Allegri et al, 2018, Journal of Cancer Research and Clinical Oncology CrossRef
  6. Biological and molecular effects of bromodomain and extra‐terminal (BET) inhibitors JQ1, IBET‐151, and IBET‐762 in OSCC cells
    Federica Baldan et al, 2019, Journal of Oral Pathology & Medicine CrossRef
  7. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond
    Stefania Bulotta et al, 2020, Current Opinion in Oncology CrossRef
  8. Network-based meta-analysis for the identification of potential target for human anaplastic thyroid carcinoma
    Leimarembi Devi Naorem et al, 2020, Meta Gene CrossRef
  9. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation
    Elisabetta Molteni et al, 2023, International Journal of Molecular Sciences CrossRef
  10. Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells
    Lorenzo Allegri et al, 2021, International Journal of Molecular Sciences CrossRef
  11. The effect of Apigenin on glycometabolism and cell death in an anaplastic thyroid cancer cell line
    Shabnam Heydarzadeh et al, 2023, Toxicology and Applied Pharmacology CrossRef
  12. Osteogenic and Adipogenic Differentiation Potential of Oral Cancer Stem Cells May Offer New Treatment Modalities
    Milica Jaksic Karisik et al, 2023, International Journal of Molecular Sciences CrossRef
  13. Dose and drug changes in chronic lymphocytic leukemia cell response in�vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors
    Małgorzata Kubczak et al, 2019, Molecular Medicine Reports CrossRef